Expression characteristics and detection value of Ki67, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) in patients with breast cancer.

Weiwei Qian, Yi Ni, Zihan Wang, Fei Yin

Abstract read

In one paragraph

Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

miR-1911-3p Regulates Malignant Biological Behaviors and Glycolytic Activity of Triple-Negative Breast Cancer via FBLN5.Breast cancer (Dove Medical Press) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Weiwei QianWeiwei Qian, Department of Thyroid and Breast Surgery, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu Province 226001, P.R. China, Department of Thyroid and Breast Surgery, Nantong Third People's Hospital, Nantong, Jiangsu Province 226001, P.R. China.

Yi NiYi Ni, Department of Thyroid and Breast Surgery, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu Province 226001, P.R. China, Department of Thyroid and Breast Surgery, Nantong Third People's Hospital, Nantong, Jiangsu Province 226001, P.R. China.

Zihan WangZihan Wang Department of Surgery, School of Medicine, Nantong University, Nantong, Jiangsu Province 226000, P.R. China, Department of Thyroid and Breast Surgery, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu Province 226001, P.R. China, Department of Thyroid and Breast Surgery, Nantong Third People's Hospital, Nantong, Jiangsu Province 226001, P.R. China.

Fei YinFei Yin, Department of Thyroid and Breast Surgery, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu Province 226001, P.R. China, Department of Thyroid and Breast Surgery, Nantong Third People's Hospital, Nantong, Jiangsu Province 226001, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the expression characteristics of Ki-67, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) in breast cancer (BC) patients and to evaluate their associations with lymph node metastasis and clinical disease stage. Methodology: The clinicopathological data of 122 patients with BC admitted to Affiliated Nantong Hospital 3 Results: Patients with lymph node metastasis had a significantly higher Ki67 labeling index and significantly lower ER and PR labeling indices than those without lymph node metastasis (all Conclusions: BC patients exhibit characteristic alterations in Ki67, ER, and PR immunohistochemical expression, and the degree of Ki67 increase together with ER and PR decrease is closely associated with lymph node metastasis and clinical disease stage. These findings suggest that combined assessment of these biomarkers may be useful for risk stratification and staging in breast cancer.

Indexed as

Breast cancerEstrogen ReceptorHuman epidermal growth factor receptor 2Progesterone Receptor

Identifiers

PMID41737182

DOI10.12669/pjms.42.1.13351

PMCPMC12927171

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.